CELLINK to partner with Made In Space to advance bioprinting technology in space
CELLINK today announced its partnership with Made In Space, Inc. (MIS), the industry leader for space manufacturing technologies, to develop advanced bioprinting technology for space. The partnership looks to combine MIS expertise in additive manufacturing in microgravity with CELLINK’s innovative bioprinting technologies and leverage the microgravity environment to gain insights that could improve drug screening and cancer research on Earth.
“CELLINK supports space programs in the United States with our deep commitment to cutting-edge innovation, extensive portfolio of technologies and world-class team of scientists and engineers,” said CELLINK co-founder and CEO Erik Gatenholm. “We are excited to partner with Made In Space to refine bioprinting technologies that can support and enhance future missions in spaceflight and space exploration.”
Through this strategic partnership, CELLINK and MIS intend to align their technical competencies and identify technology development opportunities across several pathways including the International Space Station and future platforms.
Bioprinting has the potential to mitigate crew health and safety risks on long-duration spaceflight missions where access to standard medical facilities isn’t readily available. Bioprinting capabilities optimized to operate in the space environment could enable future crews to develop skin and bone patches to aid in wound healing in space.
CELLINK has prior experience in space and worked with the Swedish National Space Agency and Uppsala University to launch bioprinted stem cells on a suborbital flight onboard the MASER 14 vehicle in June 2019.
MIS was founded in 2010 and has pioneered space manufacturing capabilities in space dating back to the first demonstration of additive manufacturing in space in 2014. The company’s mission is to industrialize low-Earth orbit and support future space exploration through on-orbit manufacturing and assembly and materials development.
For more information, please contact:
CELLINK is the leading 3D bioprinter provider and the first bioink company in the world. We focus on developing and commercializing bioprinting technologies to allow researchers to print human organs and tissues for pharmaceutical and cosmetic applications. Founded in 2016 and active in more than 50 countries, CELLINK is changing the future of medicine as we know it. Visit www.cellink.com to learn more. CELLINK is listed on Nasdaq First North Growth Market under CLNK. Erik Penser Bank AB is the company’s certified adviser, available by phone at +46 846 383 00 and by email at: email@example.com.